Integrative Research Laboratories is a drug discovery and development company, developing therapeutics for the treatment of brain disorders.
Integrative Research Laboratories
Key Partners includes Integrative Invest AB, Higab Premises, EBM Premises, Hjalmarsson & Partners, R3 Revision, Setterwalls, Vedicus Strategy & Business development.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/irlab-therapeutics-ab” connections=”true” suffix=””]
IRL Team has created the proprietary Integrative Screening Process (ISP) based on phenotypic screening, physiological and pathophysiological mechanisms at the system level in the living brain and the effects of drugs and drug candidates on these mechanisms at the integrated level.
May 2018, IRLAB Therapeutics has raised SEK 138.6 million in a directed share issue to top tier investors in the US and Sweden. The share issue is directed to US based New Leaf Venture Partners, Swedens national pension funds AP2, AP3 and AP4, Handelsbanken Fonder AB, Thomas Olausson, Sven Sandberg and Alfred Berg Kapitalf_rvaltning AB.
In Dec 2015, IRL further received SEK 4.98 million, to co-finance IRL790 Phase I studies, a novel small-molecule treatment for dyskinesias and psychosis in Parkinsons Disease from VINNOVA.
In June 2014, IRL received SEK 3.8 million as development support for the IRL 790 program from VINNOVA, the Swedish Governmental Agency for Innovation Systems.